| Abstract [eng] |
Multiple sclerosis is a chronic autoimmune, inflammatory, neurodegenerative disease of the central nervous system (CNS), characterized by chronic accumulation of neurological disability. It is a major cause of non – traumatic disability among young, working-age adults (18 – 40 years) that adversely affects individual‘s social, economic and personal wellbeing. Considering highly variable disease course in patients with relapsing-remitting multiple sclerosis (RRMS), increasing attention is being directed toward a changing understanding of the disease pathophysiology. This includes recognition that vast majority of disability accrual in relapsing multiple sclerosis occurs not only due to relapse-associated worsening (RAW) but also as a result of progression independent of relapse activity (PIRA). In order to determine the most appropriate personalized disease modifying treatment (DMT) strategy that aligns with an individual patient‘s needs, it is essential to predict the likely course of disease progression and the extent of disability the patient may develop over time. To date, none of the novel developed prognostic models have been validated, therefore their use in clinical practise is not approved. For this reason, the identification and comprehensive evaluation of prognostic factors are of critical importance – both at the onset of the disease, to guide the choice of the most suitable personalized treatment strategy, and at later disease stages, to inform future treatment outcomes. This paper presents a clinical case report of RRMS patient, highlighting the significance of assessing key demographic and clinical characteristics, MRI markers and biomarkers in predicting disease progression and individual treatment prognosis. |
